Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Ingredion Incorporated | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Rationale: The dietary short-chain fructooligosaccharides have been shown to increase fecal bacterial mass and fermentation metabolites which might stimulate gut motility. Therefore, these dietary non-digestible carbohydrates might relieve functional constipation.
Objective: Study the effect of short-chain fructooligosaccharides on functional constipation.
Study design: A 16-week, randomized, placebo-controlled, double-blind cross-over trial with intervention periods of 4 weeks with a run-in period of 4 weeks and a wash-out period of 4 weeks.
Study population: Human subjects with functional constipation according to ROMEIII criteria (total n=120; male and female; 18-75 yr).
Intervention: Placebo and one out of 3 dosages of short-chain fructo-oligosaccharides, (Degree of Polymerisation of 3-5; 2, 4 and 8 g/day) for 4 weeks. scFOS will be given as oral chews.
Main study parameters: The primary parameter is the number of complete bowel movements per day in subjects with functional constipation according to Rome III criteria. Secondary outcomes are Stool consistency (Bristol Stool Scale), Stool frequency, Severity of symptoms (Constipation Scoring System; CSS) and Quality of Life (Patient Assessment of Constipation Quality of Life; PAC-QoL).
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| sc-FOS 2g/day | Experimental | Placebo (4 weeks) Short-chain fructooligosaccharide 2 g/day (4 weeks) |
|
| sc-FOS 4g/day | Experimental | Placebo (4 weeks) Short-chain fructooligosaccharide 4 g/day (4 weeks) |
|
| sc-FOS 8g/day | Experimental | Placebo (4 weeks) Short-chain fructooligosaccharide 8 g/day (4 weeks) |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| sc-FOS 2g/day | Dietary Supplement | Chewing tablets containing Short-chain fructooligosaccharides 2g/day |
|
| Measure | Description | Time Frame |
|---|---|---|
| Stool frequency (Number of complete bowel movements per day) | Change over week 4 and week 12 |
| Measure | Description | Time Frame |
|---|---|---|
| Stool consistency (Bristol Stool Scale) | Change over week 4 and week 12 | |
| Severity of symptoms (Constipation Scoring System; CSS) | Change over week 4 and week 12 | |
Not provided
Inclusion Criteria:
Age 18-75 yr
Agree to study design (signed informed consent)
At least two of the following symptoms ≥25% of the time with criteria fulfilled for the last 3 months with symptom onset at least 6 months prior to inclusion (ROME III criteria for functional constipation):
Availability of internet connection
BMI 20-30
Male or female
Willingness to abstain from functional ingredients and such as probiotics, prebiotics and foods containing high amounts of fermentable fibers and laxatives starting 1 month prior to start of the study as well as during the washout period.
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Sandra ten Bruggencate, PhD | NIZO Food Research | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| NIZO food research | Ede | Gelderland | 6718ZB | Netherlands |
Not provided
| Label | URL |
|---|---|
| Related Info | View source |
Not provided
Not provided
| ID | Term |
|---|---|
| D003248 | Constipation |
| ID | Term |
|---|---|
| D012817 | Signs and Symptoms, Digestive |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
| ID | Term |
|---|---|
| C120489 | oligofructose |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| sc-FOS 4g/day | Dietary Supplement | Chewing tablets containing short-chain Fructooligosaccharides 4g/day |
|
|
| sc-FOS 8g/day | Dietary Supplement | Chewing tablets containing short-chain Fructooligosaccharides 8g/day |
|
|
| Placebo | Dietary Supplement | Chewing tablets without short-chain Fructooligosaccharides |
|
| Quality of Life (Patient Assessment of Constipation Quality of Life; PAC-QoL) |
| Change over week 4 and week 12 |